Daniel S. Lorrain, Chief Scientific Officer: Contineum Therapeutics CTNM Planned sale · Filed 25/12/23

Trade details

Type: Planned sale notice
Stock: Contineum Therapeutics CTNM
Person: Daniel S. LorrainChief Scientific Officer
Planned sale date: 25/12/23
Filed: 25/12/23

$51.1K to be sold

Contineum Therapeutics trades, last 26 weeks

What else happened in Contineum Therapeutics around then

Filed or reported within 30 days of the trade day · 25/11/23~01/22

Daniel S. Lorrain's recent trades

Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$56K
4,170 sh
$56K
Filed 10/01
Traded 10/01
Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$154.6K
9,520 sh
$154.6K
Filed 09/01
Traded 09/01
Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$147.5K
9,520 sh
$147.5K
Filed 08/03
Traded 08/03
Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$156K
9,520 sh
$156K
Filed 07/01
Traded 07/01
Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$432.4K
28,826 sh
$432.4K
Filed 06/30
Traded 06/30

Daniel S. Lorrain, Chief Officer — plans to sell 4,170 sh of Contineum Therapeutics CTNM · $51.1K · around 12/23 · 10b5-1 plan | Whalegun